Tasly Pharmaceutical Group Co Ltd (600535) — Cash Flow-to-Debt Ratio
Tasly Pharmaceutical Group Co Ltd (600535) has a Cash Flow-to-Debt Ratio of 0.20x as of December 2025, meaning its operating cash flow of CN¥552.13 Million could theoretically repay 0% of its total liabilities (CN¥2.79 Billion) in one year. Explore 600535 long-term investments to assets to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Tasly Pharmaceutical Group Co Ltd Cash Flow-to-Debt Ratio (2001–2025)
Historical debt coverage capacity for Tasly Pharmaceutical Group Co Ltd across 25 annual periods. Also explore Tasly Pharmaceutical Group Co Ltd (600535) total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Tasly Pharmaceutical Group Co Ltd (2001–2025)
Year-by-year debt coverage analysis for Tasly Pharmaceutical Group Co Ltd. For market capitalisation and broader financial context, see Tasly Pharmaceutical Group Co Ltd stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.51x | CN¥1.42 Billion | CN¥2.79 Billion | ▼ -27.4% |
| 2024 | 0.70x | CN¥2.01 Billion | CN¥2.87 Billion | ▲ +9.9% |
| 2023 | 0.64x | CN¥2.58 Billion | CN¥4.02 Billion | ▲ +6.4% |
| 2022 | 0.60x | CN¥2.29 Billion | CN¥3.80 Billion | ▼ -30.7% |
| 2021 | 0.87x | CN¥2.80 Billion | CN¥3.23 Billion | ▲ +99.1% |
| 2020 | 0.44x | CN¥1.79 Billion | CN¥4.11 Billion | ▲ +215.2% |
| 2019 | 0.14x | CN¥1.68 Billion | CN¥12.15 Billion | ▲ +29.3% |
| 2018 | 0.11x | CN¥1.49 Billion | CN¥13.96 Billion | ▲ +263.3% |
| 2017 | -0.07x | CN¥-822.56 Million | CN¥12.56 Billion | ▼ -150.6% |
| 2016 | 0.13x | CN¥1.15 Billion | CN¥8.92 Billion | ▲ +193.2% |
| 2015 | 0.04x | CN¥340.00 Million | CN¥7.71 Billion | ▼ -43.8% |
| 2014 | 0.08x | CN¥616.76 Million | CN¥7.85 Billion | ▲ +37.7% |
| 2013 | 0.06x | CN¥346.17 Million | CN¥6.07 Billion | ▼ -54.7% |
| 2012 | 0.13x | CN¥413.31 Million | CN¥3.28 Billion | ▲ +166.6% |
| 2011 | 0.05x | CN¥135.14 Million | CN¥2.86 Billion | ▼ -75.7% |
| 2010 | 0.19x | CN¥395.05 Million | CN¥2.03 Billion | ▼ -9.8% |
| 2009 | 0.22x | CN¥400.39 Million | CN¥1.85 Billion | ▲ +12.5% |
| 2008 | 0.19x | CN¥260.21 Million | CN¥1.36 Billion | ▼ -3.0% |
| 2007 | 0.20x | CN¥221.55 Million | CN¥1.12 Billion | ▲ +116.8% |
| 2006 | 0.09x | CN¥140.56 Million | CN¥1.54 Billion | ▼ -49.5% |
| 2005 | 0.18x | CN¥214.90 Million | CN¥1.19 Billion | ▼ -26.5% |
| 2004 | 0.25x | CN¥203.27 Million | CN¥826.42 Million | ▲ +140.0% |
| 2003 | 0.10x | CN¥59.00 Million | CN¥575.74 Million | ▼ -87.4% |
| 2002 | 0.81x | CN¥206.22 Million | CN¥253.70 Million | ▲ +237.9% |
| 2001 | 0.24x | CN¥83.77 Million | CN¥348.19 Million | — |